Course Content
Sample : Interventional Cardiology
Interventional cardiology focuses on the treatment of cardiovascular diseases through catheter-based procedures rather than open-heart surgery. These techniques are minimally invasive and are commonly used to manage coronary artery disease, structural heart defects, and vascular diseases. Below are key aspects of interventional cardiology: 1. Percutaneous Coronary Intervention (PCI) Definition: A non-surgical procedure used to treat narrowing (stenosis) of the coronary arteries of the heart, often caused by atherosclerosis. Procedure: A catheter is inserted through the femoral or radial artery and threaded into the coronary arteries. A balloon is inflated at the site of the blockage to widen the artery (balloon angioplasty). A stent (a metal mesh tube) is often placed to keep the artery open. Indications: Acute coronary syndromes (ACS), including ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI). Chronic stable angina. Stent Types: Bare-metal stents (BMS): Earlier stents that are prone to restenosis. Drug-eluting stents (DES): Coated with drugs to prevent restenosis, offering better long-term outcomes. 2. Coronary Angiography Definition: A diagnostic imaging technique used to visualize the inside of coronary arteries. Procedure: A contrast dye is injected through a catheter into the coronary arteries. X-ray imaging (fluoroscopy) is used to visualize the coronary anatomy. Indications: To assess the extent of coronary artery disease (CAD). Prior to PCI or coronary artery bypass grafting (CABG). In patients with chest pain (angina) or abnormal stress tests. 3. Transcatheter Aortic Valve Replacement (TAVR) Definition: A minimally invasive procedure to replace a stenotic aortic valve without open-heart surgery. Procedure: A catheter is inserted into a large artery (usually femoral) and advanced to the heart. A balloon-expandable or self-expanding valve is delivered via the catheter and positioned at the site of the diseased aortic valve. The new valve is deployed, pushing aside the old valve and immediately improving blood flow. Indications: Severe aortic stenosis in patients at high risk or ineligible for surgical valve replacement. 4. Transcatheter Mitral Valve Repair (MitraClip) Definition: A procedure to repair a leaking mitral valve (mitral regurgitation) using a catheter-based approach. Procedure: A catheter is inserted through the femoral vein and guided to the heart. A clip is placed on the mitral valve leaflets to reduce the leak. Indications: Severe mitral regurgitation in patients who are not candidates for open-heart surgery. 5. Fractional Flow Reserve (FFR) Definition: A guide to determine the functional significance of a coronary artery stenosis. Procedure: A pressure wire is passed through a stenosis during coronary angiography. The pressure difference across the stenosis is measured before and after administering vasodilators. Indications: To assess whether a coronary stenosis is significant enough to require intervention. In borderline cases of CAD where visual estimation from angiography is inconclusive. 6. Chronic Total Occlusion (CTO) Interventions Definition: These are specialized procedures used to open completely blocked arteries that have been occluded for more than three months. Procedure: Special techniques, such as guidewire crossing and re-entry devices, are used to pass through the occluded segment. Indications: In patients with long-standing CAD and symptoms that are not relieved by medical management. 7. Peripheral Vascular Interventions Definition: These procedures address blockages in arteries outside the heart, such as the carotid arteries, renal arteries, and leg arteries. Common procedures include: Carotid artery stenting. Endovascular aneurysm repair (EVAR) for abdominal aortic aneurysm. Angioplasty and stenting for peripheral artery disease (PAD). 8. Intracoronary Imaging Intravascular Ultrasound (IVUS): Uses a catheter-based ultrasound probe to visualize the inside of coronary arteries. Helps assess plaque characteristics and optimize stent deployment. Optical Coherence Tomography (OCT): Uses infrared light to create high-resolution images of the coronary artery walls. Useful for precise evaluation of stent apposition and plaque morphology. 9. Complications of Interventional Cardiology Procedures Bleeding and vascular complications at the access site (femoral or radial artery). Coronary artery dissection or perforation during angioplasty or stent placement. In-stent restenosis (narrowing of the artery within a previously placed stent). Acute thrombosis of the stent, requiring immediate intervention. Contrast-induced nephropathy due to the use of contrast agents. 10. Post-Procedural Care Antiplatelet therapy: Dual antiplatelet therapy (DAPT) is commonly prescribed after stenting, usually with aspirin and a P2Y12 inhibitor (clopidogrel, ticagrelor). Lifestyle modification: Encouraging smoking cessation, a healthy diet, and exercise. Monitoring for restenosis: Regular follow-up with non-invasive stress tests or repeat angiography if symptoms recur.
0/5
DEVICE THERAPY IN CHRONIC HEART FAILURE (Sample)
00:30
DEVICE THERAPY IN CHRONIC HEART FAILURE Quiz
00:05:00
DEVICE THERAPY IN HYPERTENSION (Sample 2)
00:00
DEVICE THERAPY IN HYPERTENSION Quiz
00:05:00
Coronary Artery Interventions
Intervention Cardiology – Full Course
The Textbook of Interventional Cardiology covers a comprehensive array of topics essential for understanding and practicing interventional cardiology. The key areas include: Cath Lab Basics and Safety: An introduction to coronary artery anatomy, vascular access, and radiation safety in the catheterization lab. Core Procedures: In-depth discussion of coronary interventions such as percutaneous coronary interventions (PCI), chronic total occlusion management, and handling calcified coronary lesions. Diagnostic Imaging: Detailed guidance on using techniques like intravascular ultrasound (IVUS), optical coherence tomography (OCT), and fractional flow reserve (FFR) for accurate diagnosis and treatment planning. Device and Procedure-Specific Techniques: Covers the use of guidewires, stents, and hemodynamic support tools, along with guidelines for high-risk PCI. Specialized Interventions: Treatment approaches for specific conditions, including left main disease, vulnerable plaque imaging, and device therapy for heart failure and hypertension. Peripheral and Structural Interventions: Discusses interventions for lower extremity disease, renal and mesenteric arteries, and structural heart interventions such as valve repair and atrial appendage closure.
0/2
Intervention Cardiology
28:15
Coronary Bifurcation
00:00
Intervention Cardiology
00:00
00:00
About Lesson 
DEVICE THERAPY IN CHRONIC HEART FAILURE

Go through the full course via PDF Embedder (just move your cursor towards bottom left to slide pages)


		

			
		


		

Introduction

Chronic Heart Failure (CHF) remains a significant public health challenge worldwide, despite advances in pharmacotherapy. Device-based therapies have emerged as critical tools in managing patients, especially those with advanced heart failure symptoms who are not responding adequately to medical treatments. This essay reviews the landscape of device therapies for chronic heart failure, focusing on the latest guidelines, technological innovations, and regulatory pathways driving these advancements.

General Indications for Device Therapy in Heart Failure
Indication
 
Device Therapy
 
Purpose
 
Symptomatic Heart Failure Despite GDMT
 
CRT, ICD, LVAD
 
Improve heart function and reduce symptoms
 
Reduced LVEF (≤ 35%)
 
CRT, ICD
 
Synchronize ventricular contractions (CRT) and prevent sudden cardiac death (ICD)
 
Prevention of Sudden Cardiac Death (SCD)
 
ICD
 
Detect and terminate life-threatening arrhythmias
 
Heart Failure with Electrical Dyssynchrony
 
CRT
 
Improve ventricular synchrony and enhance cardiac output
 
Advanced/Refractory Heart Failure
 
LVAD
 
Mechanical support for end-stage heart failure, bridge to transplantation or destination therapy
 
Significant Secondary Mitral Regurgitation
 
MitraClip, TMVR
 
Reduce mitral regurgitation and improve symptoms
 
Severe Tricuspid Regurgitation (TR)
 
TriClip
 
Reduce TR and alleviate symptoms of right heart failure
 
Central Sleep Apnea in Heart Failure
 
Phrenic Nerve Stimulation (remedē System)
 
Stabilize breathing during sleep, reduce CSA and its impact on heart failure
 
Autonomic Dysfunction in HF
 
Baroreflex Activation Therapy (BAT), Vagus Nerve Stimulation (VNS)
 
Modulate autonomic nervous system to reduce sympathetic tone and improve symptoms
 
Volume Redistribution Congestion (HFpEF)
 
Splanchnic Nerve Blockade
 
Reduce splanchnic venous congestion and alleviate heart failure symptoms
 

Major Device Therapies for Chronic Heart Failure
  1. Cardiac Resynchronization Therapy (CRT) CRT is primarily used in patients with heart failure with reduced ejection fraction (HFrEF) and evidence of electrical dyssynchrony, such as a widened QRS complex. CRT devices improve cardiac efficiency by coordinating the contraction of the ventricles. The latest guidelines recommend CRT for patients in New York Heart Association (NYHA) functional class II-IV symptoms with an ejection fraction of 35% or less and QRS duration >150 ms.
  2. Mitral Valve Repair Devices
    • MitraClip: The MitraClip (Abbott) is used for edge-to-edge repair of the mitral valve, effectively reducing mitral regurgitation (MR) in patients with either primary or secondary MR. The COAPT trial demonstrated the device's effectiveness in reducing hospitalization and mortality rates in patients with heart failure and secondary MR who were on maximally tolerated guideline-directed medical therapy (GDMT).
    • Carillon Mitral Contour System: The Carillon system is an indirect annuloplasty device that reduces annular dilatation. It has been shown to significantly reduce mitral regurgitant volume and improve quality of life.
  3. Transcatheter Mitral Valve Replacement (TMVR) TMVR is an evolving field for patients with severe mitral regurgitation unsuitable for traditional surgery. Devices like Medtronic's Intrepid TMVR system and Abbott's Tendyne have shown promising results in reducing MR severity and improving patient outcomes.
  4. Tricuspid Valve Repair and Replacement Tricuspid regurgitation (TR) is associated with poor prognosis in heart failure, and transcatheter devices like the TriClip have been developed to address this. The TRILUMINATE Pivotal Trial demonstrated significant reductions in TR severity and improvements in quality of life in patients undergoing TriClip implantation.
  5. Baroreflex Activation Therapy (BAT) BAT targets autonomic dysfunction by stimulating baroreceptors in the carotid sinus to reduce sympathetic overactivity. The BeAT-HF trial showed improvements in NYHA functional class, quality of life, and NT-proBNP levels after six months of BAT therapy.
  6. Vagus Nerve Stimulation (VNS) VNS aims to improve autonomic balance in heart failure by increasing parasympathetic activity. Current studies like ANTHEM-HFrEF and ANTHEM-HFpEF are investigating the effectiveness of VNS in improving clinical outcomes in both HFrEF and heart failure with preserved ejection fraction (HFpEF).
  7. Cardiac Contractility Modulation (CCM) CCM involves delivering high-voltage electrical signals during the absolute refractory period of the cardiac cycle, leading to enhanced contractility without initiating a new contraction. The FIX-HF-5C trial demonstrated the benefits of CCM in improving exercise capacity and quality of life in patients with HFrEF.
  8. Phrenic Nerve Stimulation for Central Sleep Apnea (CSA) CSA is common in patients with CHF and contributes to poor outcomes. The remedē System stimulates the phrenic nerve, resulting in diaphragmatic contraction and stabilized respiration during sleep. This therapy has been shown to improve sleep quality and reduce apnea episodes.

Latest Guidelines and Recommendations

Recent updates in guidelines have emphasized the integration of these device therapies based on patient characteristics and heart failure subtypes:
  • HFrEF: CRT is recommended for patients with wide QRS and symptomatic heart failure despite optimal medical therapy. CCM and BAT can be considered for selected patients who do not meet CRT criteria.
  • HFpEF: Device therapy options remain limited; however, ongoing trials are exploring the potential benefits of VNS and other neuromodulatory devices.
  • Mitral and Tricuspid Regurgitation: Interventional therapies like MitraClip and TriClip are now recommended for patients with significant MR or TR who are at high surgical risk and are symptomatic despite GDMT.
Table: Overview of Device Therapies and Guidelines
Therapy
 
Indications
 
Trial Evidence
 
Guideline Recommendation
 
CRT
 
HFrEF, QRS > 150 ms
 
Multiple RCTs
 
Class I, Level A
 
MitraClip
 
Secondary MR, NYHA II-IV
 
COAPT
 
Class IIa, Level B
 
TMVR (Intrepid, Tendyne)
 
Severe MR, unsuitable for surgery
 
APOLLO, SUMMIT
 
Emerging evidence
 
TriClip
 
Severe TR, NYHA II-IV
 
TRILUMINATE
 
Class IIa, Level B
 
BAT
 
NYHA II-III, NT-proBNP < 1600 pg/mL
 
BeAT-HF
 
Class IIb, Level B
 
CCM (OPTIMIZER System)
 
NYHA III-IV, LVEF 25%-45%
 
FIX-HF-5C
 
Class IIb, Level B
 
Phrenic Nerve Stimulation
 
CSA in CHF
 
remedē System Pivotal
 
Class IIb, Level C
 
Indications for Device Therapy in Heart Failure

Device therapy plays a crucial role in managing patients with heart failure, particularly those who remain symptomatic despite optimized medical therapy or have specific heart failure subtypes. The indications for device therapy are guided by the type of heart failure, patient-specific characteristics, and the presence of comorbid conditions. Below is an overview of the major indications for device therapies in heart failure:

1. Cardiac Resynchronization Therapy (CRT)
  • Heart Failure Type: Heart Failure with Reduced Ejection Fraction (HFrEF)
  • Indications:
    • NYHA Class II-IV despite optimal medical therapy.
    • Left Ventricular Ejection Fraction (LVEF) ≤ 35%.
    • QRS duration ≥ 150 ms, particularly with a left bundle branch block (LBBB) pattern.
  • Purpose: CRT helps improve ventricular synchrony and is indicated to reduce morbidity and mortality in patients with significant electrical dyssynchrony.
2. Implantable Cardioverter Defibrillator (ICD)
  • Heart Failure Type: HFrEF
  • Indications:
    • Primary prevention of sudden cardiac death in patients with:
      • LVEF ≤ 35%, NYHA Class II-III, despite at least 3 months of guideline-directed medical therapy (GDMT).
    • Secondary prevention in patients with a history of ventricular arrhythmias or cardiac arrest.
  • Purpose: ICDs are used to prevent sudden cardiac death by detecting and terminating life-threatening arrhythmias.
3. Cardiac Contractility Modulation (CCM)
  • Heart Failure Type: HFrEF
  • Indications:
    • NYHA Class III-IV symptoms.
    • LVEF between 25%-45%.
    • Patients with narrow QRS (<130 ms) who are not candidates for CRT.
  • Purpose: CCM is used to improve cardiac contractility and exercise capacity in symptomatic patients who do not meet criteria for CRT.
4. Baroreflex Activation Therapy (BAT)
  • Heart Failure Type: HFrEF
  • Indications:
    • NYHA Class II-III with LVEF ≤ 35%.
    • Patients with elevated NT-proBNP levels who are not suitable candidates for CRT.
  • Purpose: BAT helps in autonomic modulation by reducing sympathetic tone and improving symptoms and quality of life.
5. Mitral Valve Repair (e.g., MitraClip)
  • Heart Failure Type: HFrEF and Heart Failure with Preserved Ejection Fraction (HFpEF)
  • Indications:
    • Symptomatic patients with significant secondary mitral regurgitation despite optimized GDMT.
    • LVEF between 20%-50% and NYHA Class II-IV symptoms.
  • Purpose: The MitraClip device is used to reduce mitral regurgitation, improve symptoms, and decrease hospitalizations.
6. Transcatheter Mitral Valve Replacement (TMVR)
  • Heart Failure Type: HFrEF and HFpEF
  • Indications:
    • Patients with symptomatic, moderate to severe mitral regurgitation who are at high or prohibitive surgical risk.
  • Purpose: TMVR is aimed at improving mitral valve function, reducing regurgitation, and alleviating heart failure symptoms.
7. Tricuspid Valve Repair and Replacement (e.g., TriClip)
  • Heart Failure Type: Right Heart Failure, Biventricular Failure
  • Indications:
    • Severe tricuspid regurgitation (TR) in symptomatic patients with NYHA Class II-IV despite optimal medical therapy.
  • Purpose: Tricuspid valve repair devices are used to reduce TR, which can significantly alleviate symptoms and reduce right-sided heart failure burden.
8. Phrenic Nerve Stimulation for Central Sleep Apnea (e.g., remedē System)
  • Heart Failure Type: HFrEF and HFpEF
  • Indications:
    • Patients with central sleep apnea (CSA) that worsens heart failure and contributes to poor quality of life.
  • Purpose: Phrenic nerve stimulation helps to stabilize breathing during sleep, reducing the impact of CSA on heart failure progression.
9. Left Ventricular Assist Devices (LVAD)
  • Heart Failure Type: End-Stage Heart Failure
  • Indications:
    • Patients with advanced heart failure who are refractory to GDMT and are not eligible for heart transplantation.
  • Purpose: LVADs are used as a bridge to transplantation or as destination therapy to prolong survival and improve quality of life in patients with end-stage heart failure.
10. Splanchnic Nerve Blockade
  • Heart Failure Type: Heart Failure with Preserved Ejection Fraction (HFpEF)
  • Indications:
    • Patients with evidence of intravascular volume redistribution leading to congestion despite normal total body fluid volume.
  • Purpose: Splanchnic nerve modulation aims to reduce splanchnic venous congestion and alleviate heart failure symptoms.

Summary Table: Indications for Device Therapy in Heart Failure

Device Therapy
 
Indications
 
HF Type
 
CRT
 
LVEF ≤ 35%, QRS ≥ 150 ms, NYHA II-IV
 
HFrEF
 
ICD
 
LVEF ≤ 35%, NYHA II-III, history of arrhythmias
 
HFrEF
 
CCM
 
LVEF 25%-45%, NYHA III-IV, narrow QRS
 
HFrEF
 
BAT
 
NYHA II-III, LVEF ≤ 35%, NT-proBNP < 1600 pg/mL
 
HFrEF
 
MitraClip
 
Significant secondary MR, LVEF 20%-50%
 
HFrEF, HFpEF
 
TMVR
 
Moderate to severe MR, unsuitable for surgery
 
HFrEF, HFpEF
 
TriClip
 
Severe TR, NYHA II-IV
 
Right HF, Biventricular HF
 
Phrenic Nerve Stimulation
 
Central Sleep Apnea with HF
 
HFrEF, HFpEF
 
LVAD
 
End-stage HF, refractory to GDMT
 
End-Stage HF
 
Splanchnic Nerve Blockade
 
Volume redistribution congestion, HFpEF
 
HFpEF
 
 

 

Previous
Next
0% Complete